by Lupus Foundation, Ohio | Jan 9, 2026 | Lupus Foundation of America, News & Events
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary and exploratory endpoints in adults with systemic lupus...
by | Dec 18, 2025 | Lupus Foundation of America, News & Events
A new study finds that experiences of discrimination are associated with worse patient-reported lupus-related symptoms and depressive symptoms among people with systemic lupus erythematosus (SLE). Patient-reported disease activity such as pain, fatigue and depression...
